<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186456</url>
  </required_header>
  <id_info>
    <org_study_id>SCLnow-IMIMH-02</org_study_id>
    <nct_id>NCT03186456</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction</brief_title>
  <official_title>Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sclnow Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sclnow Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the study is to determine the safety and efficacy of treating acute ischemic&#xD;
      stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, paralleled study. 40 patients will be separated into two&#xD;
      groups, and receive basic treatment (Aspirin Tablet). Patients in experimental group will&#xD;
      receive hUC-MSC once a month, total 3 times. After the treatment, investigator will have&#xD;
      follow-up visit for 6 months, evaluate the security and efficacy of hUC-MSC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Others&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related-adverse events counting</measure>
    <time_frame>26 weeks</time_frame>
    <description>patients will be monitored for any adverse events resulting from the treatment of Human Umbilical Cord Mesenchymal Stem Cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>26 weeks</time_frame>
    <description>After the first time transplantation, follow-up visit for 26 weeks. Based on Modified Rankin Scale, counting the percentage of different symptom changes to evaluate MSC efficacy:&#xD;
the percentage of participants run from 0-1, no symptom or no significant disability.&#xD;
the percentage of participants run from 0-2, no symptom or slight disability.&#xD;
the percentage of participants decline 2 scales compare to baseline.&#xD;
the percentage of participants decline 1 scale compares to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel activities of daily living (ADL) Index</measure>
    <time_frame>26 weeks</time_frame>
    <description>Based on Activity of Daily Living Scale (ADL) to counting the percentage of patients in following condition:&#xD;
the percentage of patients with score &gt; 75&#xD;
the decline of Barthel ADL Index range compares to baseline. Evaluate the efficacy of MSCs treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH stroke scale (NIHSS)</measure>
    <time_frame>26 weeks</time_frame>
    <description>According to NIHSS changes after the treatment, evaluate MSCs efficacy by counting the percentage of patients in following condition:&#xD;
the percentage of patients with score 0-1;&#xD;
the percentage of patients with score declined 7 compare to baseline;&#xD;
the percentage of patients with score declined 50% compare to baseline;&#xD;
the declined ranges compare to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aspirin Tablet, 100mg/d; Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)</intervention_name>
    <description>Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 *10^6/kg. once a month, total 3 times.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Tablet</intervention_name>
    <description>Drug: Aspirin Tablet, 100 mg/d</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient within 2 weeks onset of symptoms.&#xD;
&#xD;
          -  Symptoms and signs of clinically definite acute cerebral infarction patients.&#xD;
&#xD;
          -  CT/MRI prove the Oxfordshire Community Stroke Project (OCSP) as Total Anterior&#xD;
             circulation infarct (TACI), Partial Anterior circulation infarct (PACI), Posterior&#xD;
             Anterior circulation infarct (POCI), or obvious neurological deficit lacunar&#xD;
             infarction patient.&#xD;
&#xD;
          -  Signed informed consent after understanding all possible benefits and harm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergic to basic drug&#xD;
&#xD;
          -  with progressive stroke, transient ischemia attach, cerebral infarction with posterior&#xD;
             cerebral hemorrhage, and cerebral arteritis.&#xD;
&#xD;
          -  tumor, injury, and parasites caused cerebral embolism&#xD;
&#xD;
          -  rheumatic heart disease, coronary heart disease, and other atrial fibrillation&#xD;
             combined heart disease caused cerebral embolism&#xD;
&#xD;
          -  subject is processing thrombolytic therapy&#xD;
&#xD;
          -  subject is pregnancy and of childbearing potential or breast feeding&#xD;
&#xD;
          -  participate in any other clinical trial in last 3 months&#xD;
&#xD;
          -  bleeding tendency patient; severe bleeding tendency in last 3 month&#xD;
&#xD;
          -  with gastric duodenal ulcer&#xD;
&#xD;
          -  participants with severe liver and kidney, hematopoietic, and metabolic diseases; Or&#xD;
             with liver and kidney function examination abnormal&#xD;
&#xD;
          -  participants are intolerance with Aspirin Enteric-coated Tablets, or need other&#xD;
             antiplatelet drugs&#xD;
&#xD;
          -  participants: alcoholism, drug addicted, or other situations may complicated the&#xD;
             results&#xD;
&#xD;
          -  under other therapy that possibly influence MSC security or efficacy&#xD;
&#xD;
          -  investigator supposes not suitable to participate this clinical trail&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Temuqile</last_name>
    <role>Study Director</role>
    <affiliation>Inner Mongolia International Mongolian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Guo, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>China-Japan Union Hospital, Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inner Mongolia International Mongolian Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute cerebral infarction</keyword>
  <keyword>umbilical cord mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

